Latest Research And Development News

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

Advanced Braking Technology Ltd (ASX: ABV) reported a 28% jump in product sales revenue to $6 million for Q3 FY26, driven by strong aftermarket sales and international market traction. The company also advanced certification of its autonomous BRAKEiQ system, targeting FY27 adoption.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Neometals has secured A$7.9 million through a placement and launched a concurrent A$5.1 million entitlement offer to fund gold production at Barrambie and advance lithium exploration in Utah. The capital raise supports a near-term production joint venture and aggressive resource expansion.

Talius Group has reported its second consecutive quarter of positive operating cash flow, alongside an 11% annual increase in subscriptions and a $1.81 million revenue haul for Q1 FY26. The appointment of Pat Howard as CEO and a new $567k contract with Seventh-Day Adventist Aged Care signal momentum in the company’s push toward scalable growth.

Electro Optic Systems (ASX: EOS) wraps up a three-year turnaround, reporting a $459 million order backlog despite a 27% revenue drop. The company expands its counter-drone and space control portfolio with the acquisition of the UK-based Interceptor business and a pending deal for MARSS, a European command-and-control software provider.

Connexion Mobility reported a record $3 million quarterly revenue, boosted by exclusive software deployment for GM Canada’s Enhanced Exposure Program, while net profit before tax fell 31% due to higher expenses.

Marquee Resources (ASX:MQR) has secured a non-exclusive R&D patent licence with Oak Ridge National Laboratory, granting access to NEAREST technology tailored for clay-rich rare earth deposits like Redlings in WA. This partnership could reshape processing efficiency and environmental impact for Marquee’s significant inferred resource.

Truscott Mining’s maiden 2026 drilling at Westminster confirms shear-hosted gold mineralisation and sets the stage for diamond drilling and resource upgrades. Management changes and mining lease applications signal a push towards production.

Legend Mining has identified significant chargeable-resistive features at its Pinnacle Well Project, enhancing gold prospectivity at Alpha North and Pyrophyllite Hill. The company is progressing drill approvals aiming for a July start, supported by a solid $10.2 million cash balance.

EMVision Medical Devices has ramped up recruitment in its pivotal FDA trial across eight hospitals and is nearing results from multiple pre-hospital studies, all while bolstering its cash position with a $3.8 million R&D tax refund and $6.6 million in grant funding.

Ainsworth Game Technology Limited has released its Target’s Statement recommending shareholders accept an unconditional proportional off-market takeover bid by Mr Kjerulf David Hastings Ainsworth at $1.30 per share, representing a premium to recent trading prices.